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Journal of Cystic Fibrosis 13 (2014) 241–242At last, Burkholderia spp. is one of the inclusion criteria — A
negative (but published) randomised controlled trialThis edition of the Journal of Cystic Fibrosis sees the pub-
lication of the negative results from the multicentre study of
nebulised aztreonam in CF patients with chronic Burkholderia
infection [1]; what is unusual about this?
On 3rd January 2014, in the UK, the House of Commons
Committee of Public Accounts published a report on access to
clinical trial information, specifically relating to influenza therapy
[2]. In their summary they stated “…important information about
clinical trials is routinely and legally withheld from doctors and
researchers by manufacturers. This longstanding regulatory and
cultural failure impacts on all of medicine, and undermines the
ability of clinicians, researchers and patients to make informed
decisions about which treatment is best”. As long ago as 1986,
Professor RJ Simes pointed out that published clinical trial
literature may be biased in favour of positive or promising results
[3]. Giving evidence to the Parliamentary Committee, Dr Ben
Goldacre said that a National Institute for Health Research
(NIHR) review in 2010 estimated that the chance of completed
trials being published is about half, but that trials with positive
results were about twice as likely to be published compared to
negative ones [2]. This has been backed up by a Cochrane
systematic review, which concluded that trials with positive
findings (defined as statistically significant, or a positive direction
of treatment effect, or results perceived as being ‘important or
striking’) had nearly four times (with 95% confidence interval
2.7–5.7) the odds of being published compared to negative trials
[4]. Assuming a strong hypothesis, an important question, robust
methodology with adequate recruitment to satisfy power
calculations, a study should always be publishable, even if the
results are negative.
In theory, trial registries should improve this situation. From
2005 the International Committee of Medical Journal Editors
(ICMJE) mandated that a trial needed to have been registered in a
clinical trials registry for it to be considered for later publication [5].
This should at least alert researchers that a trial is being carried out
and results should be expected, although inevitably it is the
presentation at a conference or the actual publication that brings
the results to the attention of the medical community. However
a study in 2011 showed that only 1 in 5 trials registered on
ClinicalTrials.gov (that anyway were subject to mandatory
reporting due to FDA legislation), had been reported within1569-1993/$ -see front matter © 2014 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2014.01.0031 year of the completion of the trial [6]. Of course some may have
been published after that, but there is a delay in publication of
studies with negative results compared to positive ones, which
a Cochrane review showed was about 1 year [7,8]. Recent
legislation has been agreed by the European Parliament (EU
Clinical Trials Directive) that ensures all clinical trials are
registered, and once completed, are made publicly available. The
European ombudsman has stated that there is no ‘commercially
confidential information’ in clinical trial protocols or reports, and
that the interests of public health and the citizens' right to know
should overcome any claim by drug companies that commercial
confidentiality should allow trial results to be withheld. However
Peter Gøtzsche, director of the Nordic Cochrane Centre, does not
believe the new legislation goes far enough [9].
Are editors of journals biased towards positive studies? Whilst
one would like to think this was not the case, we could only be
certain by knowing the acceptance/rejection rates of positive and
negative studies. In fact an NIHR Health Technology Assessment
found that publication bias occursmainly before the presentation of
findings at conferences, and before submission of manuscripts to
journals [10]. More likely pharmaceutical companies are suppress-
ing studies that are ‘bad news’ for their profit margin. This is
backed up by a study of 546 drug trials registered in 1999 on
ClinicalTrials.gov [11]. Trials were sponsored by industry (63%),
government sources (14%) or non-profit organisations (23%), and
overall 66% had been published. Industry-funded trials had
positive outcomes in 85% publications, compared to 50% of
government trials, and 72% of non-profit organisations. This
significant difference is most likely due to publication bias by the
drug companies, although there are other factors that may be
involved, for example investigator's failure to write up and submit.
In a study published 15 years ago, 178 abstracts of randomised
controlled trials (RCTs) presented at Cystic Fibrosis (CF)
conferences were analysed, and in 167 a conclusion could be
drawn as to whether the results were positive or negative [12].
There was no difference in the subsequent publication rate between
the two categories, although overall it was rather low — 32%.
However bias may have already crept in, as 115/167 (69%) of the
abstracts presented had positive results. More recently, a study of
142 CF trials registered with ClinicalTrials.gov found that only
44% had been published, after a median of 3.25 years; they foundby Elsevier B.V. All rights reserved.
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they did not analyse positive vs negative trials [13]. Nevertheless,
there are quite a few negative studies published in the CF literature,
some of which have made large contributions to our understanding
of how best to treat CF. Examples include trials of the leukotriene
B4 antagonist amelubant; recombinant α1-antitrypsin; inhaled
corticosteroids; ataluren (PTC124); ivacaftor for homozygous
p.Phe508del mutation; denufosol; nebulised amiloride; miglustat;
and high frequency chest wall oscillation (the Vest).
And so to the paper; Elizabeth Tullis et al. present results from
the multicentre (35 centres in North America) RCT of three times
daily nebulised aztreonam in 100 CF patients with chronic
Burkholderia infection [1]. Unfortunately the results are
disappointing, as despite 24 weeks of continuous nebulised
aztreonam, there was no statistical advantage seen compared
to placebo for any of their outcomes (lung function, exacerbations
requiring antibiotics, or hospitalisations). As usual, the study was
powered for change in lung function, and they did at least reach
their recruitment target. However there was a ‘trend’ to less
use of intravenous, oral and/or inhaled antibiotics used for any
respiratory indication, with the maddening p values of 0.06 and
0.071. One wonders whether that might be a type II error and
perhaps aztreonam has some benefits that were missed due to
insufficient numbers.
The study was sponsored by Gilead Sciences Inc. and given the
discussion above, it is good that the results are in the public domain
(they were also presented at the 2011 North American CF
Conference). All are to be congratulated as this is the largest study
of inhaled antibiotics in CF patients with chronic Burkholderia
infection. In fact the 2012 Cochrane systematic review found no
study of antibiotic use for chest exacerbations in CF patients with
chronic Burkholderia cepacia complex infection [14]. Further-
more, I am only aware of one other published RCT in CF patients
with Burkholderia cepacia; nebulised taurolidine was studied
in 20 adults [15]. Given the seriousness of this organism, it is
rather surprising that so little is published. It is standard to see
Burkholderia infection as an exclusion criterion for entry into
practically every therapeutic trial in CF. Presumably this started
out as a logistical issue of patient segregation in research facilities,
or perhaps patient numbers were too small in the past, but it
almost seems as if there is a prejudice against these patients being
in trials. An orphan complication of an orphan disease! This study
should help pave the way for further studies to improve the
respiratory health of patients with Burkholderia infection.Conﬂict of interest statement
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